In August, a single email triggered a chain of hand-wringing and strategizing inside one of America’s largest medical technology companies: A reporter asked Boston Scientific if the biotech ...

Yeast and white rot fungus could have a small but ingenious role to play in the energy transition. View on euronews ...

The walls were covered with vinyl wallpaper when Lorde moved in. That’s gone, replaced by white-painted walls that make her art collection the central focus. The white walls also lend cohesion ...

Biotechnology contributes to this aspect of the plastics industry while providing end-of-life waste management solutions via enzymatic recycling, facilitating monomer recovery under milder conditions ...

Microsoft has been working on dynamic animated wallpapers for Windows 11 for a few years, and now a former designer has revealed exactly what they look like. Sergey Kisselev, a former motion ...

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...

Unfortunately, dynamic wallpapers as a feature is yet to actually ship for Windows 11, suggesting the feature may have been canceled, or at the very least postponed.

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...

Did you know that you can optimise your noise-cancellation settings? Noise-cancellation technology allows users to tweak settings by running an analysis of new and different conditions. The optimise ...

Local biotech Heron Therapeutics is relocating its headquarters from San Diego to North Carolina, where it says the area’s burgeoning biotech scene “provides ample space for growth and ...

Va­lo Health’s di­a­bet­ic retinopa­thy drug failed to im­prove pa­tients’ symp­toms in a Phase 2 study, and the com­pa­ny is now on the hunt for a … ...